1040.9500 -8.65 (-0.82%)
NSE Nov 20, 2026 15:31 PM
Volume: 191.2K
 

1040.95
-0.82%
ICICI Securities Limited
Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.
Alembic Pharmaceuticals Ltd. is trading above all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended